Is Cemiplimab available in China?

Cemiplimab (Cemiplimab) is an innovative anti-cancer drug that is part of immunotherapy. Its primary use is to treat advanced squamous non-small cell lung cancer (SCC) with high expression of PD-L1 (programmed death ligand -1). Cimepilimab is unique in its mechanism of action. It is an immune checkpoint inhibitor designed to enhance the immune system's attack on cancer cells.

Cimeplimab is not currently available in China, so patients cannot purchase it domestically and need to purchase cimeplimab through overseas channels. There are only cimepri monoclonal original drugs abroad, mainly European and American versions. The European version is about 40,000, and the American version is about 100,000. Both are original drugs, and their drug ingredients and efficacy are the same.

Its mechanism of action is to inhibit the binding of PD-1 receptors to PD-L1 ligands, thereby releasing the inhibition of T cells, thereby enhancing the immune system's recognition and attack of cancer cells. This treatment reverses immune evasion mechanisms, allowing the patient's immune system to fight cancer cells more effectively. In patients with high PD-L1 expression, cimepilimab has been shown to significantly extend survival, bringing new hope to patients with advanced lung cancer.

However, the use of cimipilimab may be associated with adverse reactions such as fatigue, rash, nausea, diarrhea, and immune-related adverse events such as immune thyroid disease. Therefore, patients should fully discuss the potential risks and benefits with their doctor before receiving treatment and strictly follow medical recommendations.

Cimepilimab represents an innovation in cancer treatment, especially for patients who have failed traditional treatments. It provides these patients with a new treatment option that can extend survival, improve quality of life, and provide new hope for patients and medical professionals. In clinical practice, the successful application of cimepilimab marks an important breakthrough in immunotherapy in cancer treatment.